Cara Therapeutics CARA 深 滬
等待開盤 04-01 09:30:00 美东时间
5.32
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 5.32
- 總市值 2433.16万
- 52周最高 31.32
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.1252
- 委 比 0.00%
- 總股本 457.36万
- 歷史最高 1067.292
- 量 比 0
- 振 幅 0.00%
- 歷史最低 8.1252
- 每 手 1
- 風險率 0.62%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Houston-based biopharmaceutical company Tvardi Therapeutics announced financial results for Q4 and FY 2025, highlighting progress in their Phase 2 trials for STAT3 inhibitors TTI-101 and TTI-109. The company reported a 9.4% reduction in fibrosis score versus placebo in its IPF trial, with plans for H2 2026 topline data from the HCC trial of TTI-101 and Q2 2026 results from the healthy volunteer study of TTI-109. The cash runway is expected to sus...
03-31 20:01
Foghorn Therapeutics appoints Ryan Maynard as CFO
Foghorn Therapeutics (FHTX) said on Monday that Ryan Maynard will join the clinical-stage biotech as CFO effective Feb. 23, 2026. Maynard brings over 25 years of executive experience in biopharma and ...
02-23 20:27
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics appoints Ryan Maynard as Chief Financial Officer, bringing over 25 years of experience in biopharmaceutical finance. Maynard previously led financial strategy at Cara Therapeutics and has extensive experience in fundraising and FDA approvals. His expertise is expected to support Foghorn's growth and advancement of its therapeutic pipeline, including partnerships and selective degrader portfolio development.
02-23 12:00
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
Cardiff Oncology announced leadership changes amid its growth phase. CEO Mark Erlander and CFO James Levine have stepped down, with Dr. Mani Mohindru, a board member, appointed interim CEO. The company seeks permanent replacements for both roles. Cardiff's lead product, onvansertib, a PLK1 inhibitor, is in mid-stage trials for RAS-mutated colorectal cancer and being evaluated in other cancers. Dr. Mohindru brings extensive biotech experience and ...
01-27 12:00
Carasent AB Launches SEK 150 Million Share Buy-Back Program
An update from Carasent AB ( ($SE:CARA) ) is now available. Carasent AB has ann...
2025-07-10 01:32
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
2025-06-13 03:08
Bearish Tuesday For Marijuana Stocks - Rocky Mountain High, Cara Therapeutics Among Top Gainers
GAINERS: CLS Holdings USA (OTC:CLSH) shares closed up 12.00% at $0.03 Cipher P...
2025-04-16 04:30
BRIEF-Cara Therapeutics Announces 1-For-3 Reverse Stock Split
April 14 (Reuters) - Cara Therapeutics Inc CARA.O: CARA THERAPEUTICS ANNOUNCES 1-FOR-3 REVERSE STOCK SPLIT IN CONNECTION WITH THE PROPOSED MERGER WITH TVARDI THERAPEUTICS Source text: ID:nGNX8kfqG2 Fu...
2025-04-15 01:27
BUZZ-Cara Therapeutics rises after announcement of reverse stock split
** Shares of biopharma firm Cara Therapeutics CARA.O rise 14.5% to $5.61 ** Cara says that its board has approved a 1-for-3 reverse stock split, effective April 15 ** Cara entered into a merger agreem...
2025-04-15 00:36
